Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer

Journal of Clinical Oncology

Volumn 15, Issue 5, 1997, Pages 1906-1915

  Gianni, L ^a   Vigano L ^a   Locatelli, A ^a   Capri, G ^a   Giani, A ^a   Tarenzi, E ^a   Bonadonna, G ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPHENIRAMINE; CREMOPHOR; DOXORUBICIN; DOXORUBICINOL; DRUG METABOLITE; GLYCOPROTEIN P; HYDROCORTISONE; PACLITAXEL; PACLITAXEL DERIVATIVE; PREDNISONE;

ADULT; AGED; ARTICLE; BOLUS INJECTION; BREAST CANCER; CANCER CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG INFUSION; DRUG RETENTION; FEMALE; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

EID: 0030977999     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.5.1906     Document Type: Article

References (23)

1. Huizing MT, Keung AC, Rosing H, et al: Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11:2127-2135, 1993
2. Sonnichsen DS, Hurwitz CA, Pratt CB, et al: Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol 12:532-538, 1994
3. Gianni L, Kearns CM, Giani A, et al: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13:180-190, 1995
4. Rowinsky EK, Gilbert MR, McGuire WP, et al: Sequence of Taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol 9:1692-1703, 1991
5. Kennedy MJ, Zahurak ML, Donehower RC, et al: Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously untreated metastatic breast cancer. J Clin Oncol 14:783-791, 1996
6. Holmes FA, Valero V, Walters RS, et al: The M.D. Anderson Cancer Center experience wint Taxol in metastatic breast cancer. Monogr Natl Cancer Inst 15:161-169, 1993
7. Sledge GW Jr: Doxorubicin/paclitaxel combination chemotherapy for metastatic breast cancer: The Eastern Cooperative Oncology Group experience. Semin Oncol 22:123-125, 1995
8. Holmes FA, Newman EA, Madden T, et al: Schedule dependent pharmacokinetics in a phase I trial of Taxol and doxorubicin as initial chemotherapy for metastatic breast cancer. Ann Oncol 5:191, 1994 (abstr: suppl 5)
9. Gianni L: Theoretical and practical aspects of paclitaxel scheduling. Ann Oncol 6:861-863, 1995 (editorial)
10. Gianni L, Munzone E, Capri G, et al: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose- and sequence-finding study. J Clin Oncol 13:2688-2699, 1995
11. Rocci ML, Jusko WJ: LAGRAN program for area and moments in pharmacokinetic analysis. Comput Prog Biomed 16:293-296, 1983
12. Scala S, Budillon A, Zhan Z, et al: Downregulation of mdr-1 expression by 8-Cl-cAMP in multidrug resistant MCF-7 human breast cancer cells. J Clin Invest 96:1026-1034, 1995
13. Gottesman MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann Rev Biochem 62:385-427, 1993
14. Fojo AT, Akijama S, Gottesman MM, et al: Reduced drug accumulation in multidrug resistant human KB carcinoma cells lines. Cancer Res 45:3002-3007, 1985
15. Fisherman JS, Cowan KH, Noone M, et al: Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer. J Clin Oncol 14:774-782, 1996
16. Sledge GW Jr, Robert N, Sparano JA, et al: Paclitaxel (Taxol)/ doxorubicin combinations in advanced breast cancer: The Eastern Cooperative Oncology Group experience. Semin Oncol 21:15-18, 1994
17. Holmes FA, Madden T, Newman RA, et al: Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol 14:2713-2721, 1996
18. Millward LK, Cosson EJ, Stokes KH, et al: Cremophor EL changes the pharmacokinetics of doxorubicin. Proc Annu Meet Am Assoc Cancer Res 36:373, 1995 (abstr 2221)
19. Praga C, Trave F, Petroccione A: Anthracycline-induced cardiotoxicity and its relevance in cancer treatment, in Nimmo WS (eds): Clinical Measurement in Drug Evaluation. London, United Kingdom, Wolfe Medical Publications Ltd, 1991, pp 131-142
20. Mushlin PS, Cusack BJ, Boucek RJ Jr, et al: Time-related increases in cardiac concentrations of doxorubicinol could interact with doxorubicin to depress myocardial contractile function. Br J Pharmacol 110:975-982, 1993
21. Berg SL, Cowan KH, Balis FM, et al: Pharmacokinetics of Taxol and doxorubicin administered alone and in combination by continuoous 72-hour infusion. J Natl Cancer Inst 86:143-145, 1994
22. Webster L, Linsenmeyer M, Millward M, et al: Measurement of Cremophor EL following Taxol: Plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. J Natl Cancer Inst 85:1685-1690, 1993
23. Sparreboom A, van Tellingen O, Nooijen WJ, et al: Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 56:2112-2115, 1996